Safety of Abciximab injection during endovascular treatment of ruptured aneurysms
dc.contributor.author | Gentric, Jean-Christophe | |
dc.contributor.author | Brisson, Joelle | |
dc.contributor.author | Batista, André Lima | |
dc.contributor.author | Ghostine, Jimmy | |
dc.contributor.author | Raymond, Jean | |
dc.contributor.author | Roy, Daniel | |
dc.contributor.author | Weill, Alain | |
dc.date.accessioned | 2023-05-17T19:37:10Z | |
dc.date.available | 2023-05-17T19:37:10Z | |
dc.date.issued | 2015-05 | |
dc.description.resumo | Background and purpose: We aimed to determine the safety of intra-arterial Abciximab injection in the management of thromboembolic complications during endovascular treatment of ruptured cerebral aneurysms. Methods: In a monocentric consecutive series of endovascular treatment of 783 ruptured aneurysms, 42 (5.3%) patients received Abciximab after the aneurysm was secured. Bleeding complications were registered and dichotomized as follows: new intracranial hemorrhage and peripheral bleeding. For each patient, World Federation of Neurosurgery (WFNS) sub arachnoid hemorrhage (SAH) grade, shunting, and clinical outcomes in the post-operative period and at 3–6 months were recorded. Results: SAH WFNS grades were as follows: grade I n ¼ 14, grade II n ¼ 10, grade III n ¼ 11, grade IV n ¼ 4, grade V n ¼ 3. Ten patients had intracranial hematoma additionally to the SAH prior to embolization. Four patients (9.5%) presented more blood on the post-embolization CT but only one suffered a new clinically relevant intracranial hemorrhage. Two patients (4.8%) experienced significant peripheral bleeding but none were associated with long-term disabilities. Fourteen patients had a shunt installed less than 24 h prior to Abciximab injection and one less than 48 h later. At 3–6-month follow-up, 31 patients (74%) achieved a modified Rankin Scale score (mRS) of 2 or less, six patients (14%) had a mRS of 3–5, three were dead (7%), and two were lost at follow-up. Conclusion: When the aneurysm is secured, intra-arterial Abciximab injection is a low complication rate treatment modality for thromboembolic events during embolization of cerebral ruptured aneurysm | pt_BR |
dc.identifier.citation | BATISTA, André Lima; et al. Safety of Abciximab injection during endovascular treatment of ruptured aneurysms. Interventional Neuroradiology, [S.L.], v. 21, n. 3, p. 332-336, 11 maio 2015. SAGE Publications. http://dx.doi.org/10.1177/1591019915582001. | pt_BR |
dc.identifier.doi | 10.1177/1591019915582001 | |
dc.identifier.uri | https://repositorio.ufrn.br/handle/123456789/52469 | |
dc.language | en | pt_BR |
dc.publisher | Interventional Neuroradiology | pt_BR |
dc.subject | safety | pt_BR |
dc.subject | abciximab | pt_BR |
dc.subject | cerebral aneurysm | pt_BR |
dc.subject | subarachnoid hemorrhage | pt_BR |
dc.subject | aneurysm coiling | pt_BR |
dc.title | Safety of Abciximab injection during endovascular treatment of ruptured aneurysms | pt_BR |
dc.type | article | pt_BR |
Arquivos
Licença do Pacote
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 1.45 KB
- Formato:
- Item-specific license agreed upon to submission
Nenhuma Miniatura disponível